CDK2 and cancer: CYC065 treatment was selected for analyses because this agent is undergoing clinical trial testing, and its antineoplastic effects are conferred through CDK2/9 inhibition, although the death of multipolar cancer cells was largely conferred by CDK2 antagonism (20).